Moreover, even if the level of secreted relaxin was below the detection level, the expression of RXFP1 especially in ccRCC allows us to speculate that the renal tumors can be a target of locally present RLN2 and opens the possibility to initiate the study on any relaxin therapy in renal tumors. This evidence concerns the gene RLN2 and nonpapillary renal cell carcinoma.